As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

chemically known as semaglutide, which is one of the registered products containing GLP-1 agonists from Novo Nordisk.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

Semaglutide was linked to significantly a reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs. HealthDay News — For patients with type 2 diabetes mellitus, ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...